Luspatercept for beta-thalassemia – A new horizon?
Department
Medicine
Document Type
Article
Publication Title
European Oncology and Haematology
Abstract
Several treatment options are being explored to reduce the transfusion burden and improve quality of life for patients with beta-thalassemia. One such prospect is the drug luspatercept, which has recently been approved for use in the USA for the treatment of beta-thalassemia. However, socioeconomic factors may act as a barrier to its widespread use.
First Page
16
Last Page
17
DOI
10.17925/EOH.2020.16.1.16
Volume
16
Issue
1
Publication Date
1-1-2020
Recommended Citation
Ammad Ud Din, M., & Anwer, F. (2020). Luspatercept for beta-thalassemia – A new horizon?. European Oncology and Haematology, 16 (1), 16-17. https://doi.org/10.17925/EOH.2020.16.1.16
COinS